S&P Pharmaceuticals SPDR (XPH)

The company expects full-year revenue of $255 million to $275 million, significantly higher than the $239.77 million analysts had expected.

CEO Sheldon Koenig expects to drive further revenue gains and reach operating profitability through the expansion of its bempedoic acid products in the U.S. and Europe and global expansion into key markets....

As Viatris has trailed the broader market over the past year, analysts are skeptical about its future outlook.

Despite Pfizer trailing behind the broader market over the past year, Wall Street analysts remain moderately bullish about the stock's potential.

The brokerage also pointed to potential large-scale expansion opportunities and emphasized the growing acceptance of psychedelics in future treatment paradigms.

Zoetis has significantly underperformed the broader market over the past year, yet analysts remain bullish on the stock’s prospects.

Due to Viatris’ underperformance relative to the broader S&P 500 Index over the past year, Wall Street analysts remain cautious about the stock’s prospects.

While Catalent has outperformed the broader market over the past year, analysts are cautious about the stock’s potential.

Despite Zoetis lagging behind the broader market over the past year, analysts still remain strongly bullish on the stock’s prospects.

Bristol-Myers Squibb has been lagging behind other drug manufacturers over the past three months, and analysts remain cautious about the stock's prospects.